Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIHEXYPHENIDYL HCL

All products: not a benefit

Other products in the same Health Canada class (N04A, N04AA) — coverage varies; not interchangeable

  • Ethopropazine (Parsitan): general benefit
  • Procyclidine (Pdp-Procyclidine): general benefit
  • Benztropine (PDP-Benztropine): general benefit

Artane · DIN 00015040 · 2mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-04-12 — choose a marketed DIN from the same-category list.Discontinued 1999-04-12 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-04-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-04-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Artane · DIN 00015040 Manufacturer: Lederle Division-of Cyanamid Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1999-04-12 · brand ARTANE TAB 2MG · ATC N04AA01 TRIHEXYPHENIDYL · form Tablet · route Oral · ingredients TRIHEXYPHENIDYL HYDROCHLORIDE 2 MG · company Lederle cyanamid canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Artane: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=458 · Verify on the e-Formulary ↗ (DIN 00015040)

Source record
DIN 00015040: Artane Raw flags: notABenefit=Y, sec3=Y Item: 120800018; group id 212; item number 0384; lccId None; manufacturer id LED Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00015040 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=458
Interchangeable products
Trihexyphenidyl · DIN 00545058 · $0.0376
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00015040
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1999-04-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications TRIHEXYPHENIDYL (trihexyphenidyl hydrochloride tablets) is indicated for: • Treatment of all forms of Parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). • Prevention or control of extrapyramidal disorders due to central nervous system drugs such as reserpine and the phenothiazines. 1.1. Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (>60 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustment, Geriatrics and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00085675.PDF PM date: August 7, 2026 Source product: TRIHEXYPHENIDYL; DIN 00545058; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Artane: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026